Ergomed’s interim results highlight continued progression and robust growth (+21%) in its services business. Data from one of the group’s co-development partnerships (Ferrer) is on track to deliver clinical data before the end of the year with two (Aeterna Zentaris and Dilaforette) in H1 2017. The acquisition of Haemostatix in May added a development segment to the business with a Phase II trial expected to commence next year. The Board continues to evaluate additional potential service business ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Solid interim results
- Published:
26 Sep 2016 -
Author:
Sheena Berry -
Pages:
4
Ergomed’s interim results highlight continued progression and robust growth (+21%) in its services business. Data from one of the group’s co-development partnerships (Ferrer) is on track to deliver clinical data before the end of the year with two (Aeterna Zentaris and Dilaforette) in H1 2017. The acquisition of Haemostatix in May added a development segment to the business with a Phase II trial expected to commence next year. The Board continues to evaluate additional potential service business ....